141 related articles for article (PubMed ID: 34904924)
1. Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.
Gonzalez N; Asad AS; Gómez Escalante J; Peña Agudelo JA; Nicola Candia AJ; García Fallit M; Seilicovich A; Candolfi M
Expert Opin Ther Targets; 2021 Dec; 25(12):1045-1060. PubMed ID: 34904924
[TBL] [Abstract][Full Text] [Related]
2. Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas.
Neumaier F; Zlatopolskiy BD; Neumaier B
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049661
[TBL] [Abstract][Full Text] [Related]
3. Therapies for IDH-Mutant Gliomas.
Alshiekh Nasany R; de la Fuente MI
Curr Neurol Neurosci Rep; 2023 May; 23(5):225-233. PubMed ID: 37060388
[TBL] [Abstract][Full Text] [Related]
4. Local and systemic effects of IDH mutations on primary glioma patients.
Tang F; Wang DW; Xi C; Yang JZ; Liu ZY; Yu DH; Wang ZF; Li ZQ
Immunology; 2023 Aug; 169(4):503-514. PubMed ID: 37054988
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive Determination of the IDH Status of Gliomas Using MRI and MRI-Based Radiomics: Impact on Diagnosis and Prognosis.
Li Y; Qin Q; Zhang Y; Cao Y
Curr Oncol; 2022 Sep; 29(10):6893-6907. PubMed ID: 36290819
[TBL] [Abstract][Full Text] [Related]
6. Targeting IDH1/IDH2 mutations in gliomas.
de la Fuente MI
Curr Opin Neurol; 2022 Dec; 35(6):787-793. PubMed ID: 36367045
[TBL] [Abstract][Full Text] [Related]
7. Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH-Wild-Type High-Grade Gliomas.
Ran X; Zheng J; Chen L; Xia Z; Wang Y; Sun C; Guo C; Lin P; Liu F; Wang C; Zhou J; Sun C; Liu Q; Ma J; Qin Z; Zhu X; Xie Q
Cancer Immunol Res; 2024 Feb; 12(2):232-246. PubMed ID: 38091354
[TBL] [Abstract][Full Text] [Related]
8. Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1.
Cordner R; Jhun M; Panwar A; Wang H; Gull N; Murali R; McAbee JH; Mardiros A; Sanchez-Takei A; Mazer MW; Fan X; Jouanneau E; Yu JS; Black KL; Wheeler CJ
Oncogene; 2023 Jun; 42(25):2088-2098. PubMed ID: 37161052
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Miller JJ; Gonzalez Castro LN; McBrayer S; Weller M; Cloughesy T; Portnow J; Andronesi O; Barnholtz-Sloan JS; Baumert BG; Berger MS; Bi WL; Bindra R; Cahill DP; Chang SM; Costello JF; Horbinski C; Huang RY; Jenkins RB; Ligon KL; Mellinghoff IK; Nabors LB; Platten M; Reardon DA; Shi DD; Schiff D; Wick W; Yan H; von Deimling A; van den Bent M; Kaelin WG; Wen PY
Neuro Oncol; 2023 Jan; 25(1):4-25. PubMed ID: 36239925
[TBL] [Abstract][Full Text] [Related]
10. The immunology of low-grade gliomas.
Haddad AF; Young JS; Oh JY; Okada H; Aghi MK
Neurosurg Focus; 2022 Feb; 52(2):E2. PubMed ID: 35104791
[TBL] [Abstract][Full Text] [Related]
11. The unique immune ecosystems in pediatric brain tumors: integrating single-cell and bulk RNA-sequencing.
Cao L; Xie W; Ma W; Zhao H; Wang J; Liang Z; Tian S; Wang B; Ma J
Front Immunol; 2023; 14():1238684. PubMed ID: 38094301
[TBL] [Abstract][Full Text] [Related]
12. Emerging targets for anticancer vaccination: IDH.
Platten M; Bunse L; Wick W
ESMO Open; 2021 Aug; 6(4):100214. PubMed ID: 34271312
[TBL] [Abstract][Full Text] [Related]
13. Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials.
Sharma N; Mallela AN; Shi DD; Tang LW; Abou-Al-Shaar H; Gersey ZC; Zhang X; McBrayer SK; Abdullah KG
Neurooncol Adv; 2023; 5(1):vdad053. PubMed ID: 37287696
[TBL] [Abstract][Full Text] [Related]
14. Characterization of purinergic signaling in tumor-infiltrating lymphocytes from lower- and high-grade gliomas.
Scholl JN; Weber AF; Dias CK; Lima VP; Grun LK; Zambonin D; Anzolin E; Dos Santos Dias WW; Kus WP; Barbé-Tuana F; Battastini AMO; Worm PV; Figueiró F
Purinergic Signal; 2024 Feb; 20(1):47-64. PubMed ID: 36964277
[TBL] [Abstract][Full Text] [Related]
15. RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis.
Zhang H; Cao H; Luo H; Zhang N; Wang Z; Dai Z; Wu W; Liu G; Xie Z; Cheng Q; Cheng Y
Front Immunol; 2023; 14():1086280. PubMed ID: 36776876
[TBL] [Abstract][Full Text] [Related]
16. Adenylate kinase 2 is a biomarker related to the prognosis of glioma and the immune microenvironment.
Liu Z; Tang C; Teng X; Mohamed ZA; Fan J
J Clin Lab Anal; 2023 Apr; 37(8):e24892. PubMed ID: 37161605
[TBL] [Abstract][Full Text] [Related]
17. Impact of epigenetic reprogramming on antitumor immune responses in glioma.
McClellan BL; Haase S; Nunez FJ; Alghamri MS; Dabaja AA; Lowenstein PR; Castro MG
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647827
[TBL] [Abstract][Full Text] [Related]
18. Optimize treatment approaches in isocitrate dehydrogenase (IDH) mutant gliomas: open issues.
Rudà R
Neuro Oncol; 2023 Jan; 25(1):26-27. PubMed ID: 36245275
[No Abstract] [Full Text] [Related]
19. Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies.
Wu L; Chai R; Zhao Z; Wang Q; Jiang T
Cancer Biol Med; 2022 Nov; 19(10):1423-7. PubMed ID: 36350003
[No Abstract] [Full Text] [Related]
20. Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas.
Han M; Sun Y; Zhao W; Xiang G; Wang X; Jiang Z; Xue Z; Zhou W
Front Immunol; 2022; 13():1025286. PubMed ID: 36341396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
